Human medicines European public assessment report (EPAR): Zynlonta , loncastuximab tesirine, Lymphoma, Large B-Cell, ...

Human medicines European public assessment report (EPAR): Zynlonta , loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse;Lymphoma, B-Cell, Date of authorisation: 20/12/2022, Revision: 2, Status: Authorised Human medicines European public assessment report (EPAR): Zynlonta , loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse;Lymphoma, B-Cell, Date of authorisation: 20/12/2022, Revision: 2, Status: Authorised

Wil je het laatste nieuws in jouw mailbox ontvangen?
Meld je dan aan voor de nieuwsbrief.